Exp Clin Endocrinol Diabetes 2015; 123(09): 543-547
DOI: 10.1055/s-0035-1555764
Article
© Georg Thieme Verlag KG Stuttgart · New York

The Impact of Thyroid Autoimmunity on the Clinical and Diabetes Parameters of Patients with Latent Autoimmune Diabetes in Adults

A. D. Reghina
1   Endocrinology and Diabetes Department, Elias University Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania
2   “Victor Babes” National Research and Development Institute of Pathology and Biomedical Sciences, Bucharest, Romania
,
S. Florea
1   Endocrinology and Diabetes Department, Elias University Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania
,
M. Constantin
1   Endocrinology and Diabetes Department, Elias University Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania
,
S. Fica
1   Endocrinology and Diabetes Department, Elias University Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania
› Author Affiliations
Further Information

Publication History

received 19 April 2015
first decision 19 April 2015

accepted 03 June 2015

Publication Date:
27 July 2015 (online)

Abstract

Aim: We evaluated the clinical and diabetes parameters of latent autoimmune diabetes in adults (LADA) patients according to the presence of thyroid autoimmunity (TA).

Materials and methods: Patients with LADA (diabetes onset after 30 years of age, no need for insulin treatment for at least 6 months after diabetes onset, positive for glutamic acid decarboxylase antibodies (GADA)) were evaluated for the presence of thyroid peroxidase antibodies (TPOAb) and were subjected to clinical and laboratory evaluations of the glycated hemoglobin and basal C peptide levels. The patients were stratified into either group A (with TA) or group B (without TA).

Results: We evaluated 104 (57 female and 47 male) patients with LADA. The mean age at diabetes onset was 44±10 years. The prevalence of TA among the LADA patients was 28.8% (30 patients; 23 female and 7 male). In groups A and B, the mean age at diabetes onset was 41.47±10.15 and 45.07±10 years (p=0.03), the basal C peptide level was 0.69±0.16 and 1.9±1.3 ng/ml (p<0.0001), the glycated hemoglobin level was 9.8±2.2 and 9.1±2.2 (p=0.04), and the time to insulin treatment was 3.2±2.1 years and 4.98±2.2 years (p=0.038), respectively. The use of a basal bolus insulin regimen was more frequent in group A than in group B (56.7% and 35.1%, respectively; p=0.03).

Conclusion: TA identifies a particular phenotype of LADA displaying a higher GADA titer, lower basal C peptide levels and poorer glycemic control.

 
  • References

  • 1 Groop LC, Bottazo GF, Doniach D. Islet cell antibodies identify latent type 1 diabetes in patients aged 35–75 years at diagnosis. Diabetes 1986; 35: 237-241
  • 2 Toumi T, Groop LC, Zimmet PZ et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42: 359-362
  • 3 Stenstrom G, Gottsater A, Bakhtadze E et al. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment. Diabetes 2005; 54: S68-S72
  • 4 Leslie R., David G, Williams R et al. Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 2006; 91: 1654-1659
  • 5 Zimmet PZ. The pathogenesis and prevention of diabetes in adults: genes, autoimmunity, and demography. Diabetes Care 1995; 18: 1025-1064
  • 6 Seok H, Lee WB. Latent autoimmune diabetes in adults: autoimmune diabetes in adults with slowly progressive beta-cell failure. Diabetes Metab J 2012; 36: 116-119
  • 7 Palmer JP, Hampe CS, Chiu H et al. Is latent autoimmune diabetes in adults distinct from type 1 diabetes of just type 1 diabetes at an older age?. Diabetes 2005; 54: S62-S64
  • 8 Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab 2009; 94: 4635-4644
  • 9 Brophy S, Yderstraede K, Mauricio D et al. ACTION LADA Group . Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care 2008; 31: 439-441
  • 10 Fourlanos S, Dotta F, Greenbaum CJ et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005; 48: 2206-2212
  • 11 Turner R, Stratton I, Horton V et al. for UK Prospective Diabetes Study (UKPDS) Group . UKPDS25: Autoantibodies to islet cytoplasma and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997; 350: 1288-1293
  • 12 Hawa MI, Kolb H, Schloot N et al. on behalf of the Action LADA consortium . Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype- Action LADA 7. Diabetes Care 2013; 36: 908-913
  • 13 Hossein GM, Maryam S, Saeed E et al. The prevalence of latent autoimmune diabetes in adults and its correlates in patients with type 2 diabetes in Kerman, Iran. Diabetes and Metabolic Syndrome: clinical research and review 2014; May 22. pii: S1871-4021(14)00026-5 DOI: 10.1016/j.dsx.2014.04.014. [Epub ahead of print] 2014
  • 14 Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocrine Reviews 1994; 15: 788-830
  • 15 Umpierrez GE, Latif KA, Murphy MB et al. Thyroid dysfunction in patients with type 1 diabetes: a longitudinal study. Diabetes Care 2003; 26: 1181-1185
  • 16 Kuera P, Novakova D, Behanova M et al. Gliadin, eendomysial and thyroid antibodies in patients with latent autoimmune diabetes of adults (LADA). Clinical and Experimental Immunology 2003; 133: 139-143
  • 17 Gambelunge G, Forini F, Laureti S et al. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clinical Endocrinology (Oxford) 2000; 52: 565-573
  • 18 Takeda H, Kawasaki E, Shimizu I et al. Ehime study. Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime study). Diabetes Care 2002; 25: 995-1001
  • 19 Jin P, Huang G, Lin J et al. High titre of antiglutamic acid decarboxylase autoantibody is a strong predictor of the development of thyroid autoimmunity in patients with type 1 diabetes and autoimmune diabetes in adults. Clinical Endocrinology 2011; 74: 587-592
  • 20 Buzzetti R, Di Petro S, Giaccari A et al. For the Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study Group. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 2007; 30: 932-938
  • 21 Liu L, Li X, Xiang Y et al. on behalf of the LADA China Study Group . Latent autoimmune diabetes in adults with low-titer GAD antibodies: similar disease progression with type 2 diabetes. A nationwide, multicenter prospective study (LADA China Study 3). Diabetes Care 2015; 38: 16-21
  • 22 Alberti KG, Zimmet PZ. for the WHO Consultation . Definition, diagnosis and classification of diabetes mellitus and its complications. 1. Diagnosis and classification of diabetes mellitus: provisional report of a WHO Consultation. Diabet Med 1998; 15: 539-553
  • 23 American Diabetes Association . Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35 (Suppl. 01) S64-S71
  • 24 Fourlanos S, Perry C, Stein MS et al. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 2006; 29: 970-975
  • 25 Torn C, Meeller PW, Schlosser M et al. Participating Laboratories. Diabets Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008; 51: 846-852
  • 26 Bosi EP, Garancini NT, Poggiali F et al. Low prevalence of islet autoimmunity in adult diabetes and low predictive value of islet autoantibodies in the general adult population of northern Italy. Diabetologia 1999; 42: 840-844
  • 27 Toumi T, Carlsson A, Li H et al. Clinical and genetic characteristisc of type 2 diabetes with and without GAD antibodies. Diabetes 1999; 48: 150-157
  • 28 Borg H, Gottsater A, Fernlund P et al. A 12-years prospective of the relationship between islet antibodies and β-cell function at and after the diagnosis in patients with adult onset diabetes. Diabetes 2002; 51: 1754-1762
  • 29 Hawa MI, Buchan AP, Ola T et al. LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes. Diabetes Care 2014; 37: 1643-1649
  • 30 Kasuga A, Maruyama T, Ozawa Y et al. Antibody to the M (r) 65,000 isoform of glutamic acid decarboxylase are detected in non-insulin-dependent diabetes in Japanese. J Autoimmun 1996; 9: 105-111
  • 31 Kordonouri O, Charpentier N, Hartmann R. GADA positivity at onset of type 1 diabetes is a risk factor for the development of autoimmune thyroiditis. Pediatr Diabetes 2011; 12: 31-33
  • 32 Reghina AD, Albu A, Petre N et al. Thyroid autoimmunity in 72 children with type 1 diabetes mellitus: relationship with pancreatic autoimmunity and child growth. J Pediatr Endocr Met 2012; 25: 723-726
  • 33 Murao S, Kondo S, Ohashi J et al. Anti-thyroid peroxidase antibody, IA-2 antibody, and fasting C-peptide levels predict beta cell failure in patients with latent autoimmune diabetes in adults (LADA) – A 5-year follow-up of the Ehime study. Diabetes Research and Clinical Practice 2008; 80: 114-121
  • 34 Reghina A, Macovei M, Martin S et al. Phenotypes of pacients with type 1 diabetes mellitus and autoimmune diseases. Acta Endocrinologica new series 2007; 3: 451-459
  • 35 Kawasaki E, Takino H, Yano M et al. Autoantibodies to glutamic acid decarboxylase in patients with IDDM and autoimmune thyroid disease. Diabetes 1994; 43: 80-86